NEW YORK (GenomeWeb News) — Synthetic gene company DNA2.0 and oligonucleotide synthesis shop Operon Biotechnologies today said they have formed a co-marketing alliance.
 
Terms of the deal call for Operon to co-market DNA2.0’s gene-synthesis services, while Operon’s oligos will become the “primary source” of the oligos that go into DNA2.0’s synthetic genes, the companies said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.